<!DOCTYPE html>
<html>
    <head>
        <meta charset="utf-8" />
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=1.0, maximum-scale=1.0, minimum-scale=1.0, user-scalable=no" />
        <title>Full STD Tx Guidelines</title>
        <link href="../jquery-mobile/jquery.mobile.theme-1.3.1.min.css" rel="stylesheet" type="text/css"/>
        <link href="../jquery-mobile/jquery.mobile.swatch.f.css" rel="stylesheet" type="text/css"/>
        <link href="../jquery-mobile/jquery.mobile.swatch.j.css" rel="stylesheet" type="text/css"/>
        <link href="../assets/css/custom_arrow.css" rel="stylesheet" type="text/css"/>
        <link href="../jquery-mobile/jquery.mobile.structure-1.3.1.min.css" rel="stylesheet" type="text/css"/>
        <link href="../assets/css/full.css" rel="stylesheet" type="text/css"/>
        <link href="../assets/css/recreated_tables.css" rel="stylesheet" type="text/css"/>
        <script src="../jquery-mobile/jquery-1.9.1.min.js" type="text/javascript"></script>
        <script src="../../jquery-customization.js" type="text/javascript"></script>
        <script src="../jquery-mobile/jquery.mobile-1.3.1.min.js" type="text/javascript"></script>
        <script src="../../cordova-2.7.0.js" type="text/javascript" charset="utf-8"></script>
        <script src="../assets/js/metrics.js" type="text/javascript" charset="utf-8"></script>
    </head>
    <body>
        <!-- Start of page -->
        <div data-role="page" id="g70" data-theme="d">
            <div data-role="header" data-id="guidelines-header" data-theme="j" data-position="fixed">
                <a href="lv-68.html" data-role="button" data-iconshadow="false" data-corners="false" data-theme="reset" data-transition="fade" class="back_button" role="button" aria-label="back"></a>
                <h1>Full STD Tx Guidelines</h1>
	            <a href="../menu.html" data-role="button" data-theme="reset" data-iconshadow="false" data-corners="false" class="menu_button ui-btn-right" role="button" aria-label="main menu"></a>
            </div>
            <div data-role="content">
            <div id=guidelines_breadcrumbs>
            
                    <a href="lv-47.html" >Full Guidelines</a><span class="carrot"> > </span>
                    <a href="lv-56.html" >Diseases Characterized by Genital, Anal, or Perianal Ulcers</a><span class="carrot"> > </span>
                    <a href="lv-56.html" >Genital HSV Infections</a><span class="carrot"> > </span>
                    <a href="lv-68.html" >Special Considerations</a><span class="carrot"> > </span>HIV Infection
            </div>
            </br><h4 class="sgc-1" id="sigil_toc_id_70">
 HIV Infection
</h4>
<p>
 Immunocompromised patients can have prolonged or severe episodes of genital, perianal, or oral herpes. Lesions caused by HSV are common among HIV-infected patients and might be severe, painful, and atypical. HSV shedding is increased in HIV-infected persons. Whereas antiretroviral therapy reduces the severity and frequency of symptomatic genital herpes, frequent subclinical shedding still occurs (180). Clinical manifestations of genital herpes might worsen during immune reconstitution after initiation of antiretroviral therapy.
</p>
<p>
 Suppressive or episodic therapy with oral antiviral agents is effective in decreasing the clinical manifestations of HSV among HIV-positive persons (181&ndash;183). The extent to which suppressive antiviral therapy will decrease HSV transmission from this population is unknown. HSV type-specific serologies can be offered to HIV-positive persons during their initial evaluation if infection status is unknown, and suppressive antiviral therapy can be considered in those who have HSV-2 infection.
</p>
<p>

        <div id="table">
            <div id="regimen_header">Recommended Regimens- Daily Suppressive Therapy in Persons with HIV
            </div>
            <hr/>
            <span class="regimen_text">Acyclovir 400–800 mg orally twice to three times a day
            <div id="or">OR</div>Famciclovir 500 mg orally twice a day
            <div id="or">OR</div>Valacyclovir 500 mg orally twice a day
            </span>

        </div>
 <br/>
</p>
<p>

        <div id="table">
            <div id="regimen_header">Recommended Regimens - Episodic Infection in Persons with HIV
            </div>
            <hr/>
            <span class="regimen_text">Acyclovir 400 mg orally three times a day for 5–10 days
            <div id="or">OR</div>Famciclovir 500 mg orally twice a day for 5–10 days
            <div id="or">OR</div>Valacyclovir 1 g orally twice a day for 5–10 days
            </span>

        </div>
 <br/>
</p>
<p>
 Acyclovir, valacyclovir, and famciclovir are safe for use in immunocompromised patients in the doses recommended for treatment of genital herpes. For severe HSV disease, initiating therapy with acyclovir 5&ndash;10 mg/kg IV every 8 hours might be necessary.
</p>
<p>
 If lesions persist or recur in a patient receiving antiviral treatment, HSV resistance should be suspected and a viral isolate should be obtained for sensitivity testing (184). Such persons should be managed in consultation with an HIV specialist, and alternate therapy should be administered. All acyclovir-resistant strains are resistant to valacyclovir, and the majority are resistant to famciclovir. Foscarnet, 40 mg/kg IV every 8 hours until clinical resolution is attained, is frequently effective for treatment of acyclovir-resistant genital herpes. Intravenous cidofovir 5 mg/kg once weekly might also be effective. Imiquimod is a topical alternative, as is topical cidofovir gel 1%, which is not commercially available and must be compounded at a pharmacy. These topical preparations should be applied to the lesions once daily for 5 consecutive days.
</p>
<p>
 Clinical management of antiviral resistance remains challenging among HIV-infected patients, and other preventative approaches might be necessary. However, experience with another group of immunocompromised persons (hematopoietic stem-cell recipients) demonstrated that persons receiving daily suppressive antiviral therapy were less likely to develop acyclovir-resistant HSV compared with those who received episodic therapy with outbreaks (185).
</p>

            </div>
            <script type="text/javascript">
                $('#g70').on('pageshow', function (event, ui) {
                    document.addEventListener("deviceready", function(){
                        trackFullGuidelinesPageView('70');
                                                },true);
                });
            </script>
        </div>
        <!-- end of guidelines heading page -->
    </body>
</html>

